European CHMP Adopts Positive Opinion for Treatment of All Genotypes of Chronic Hepatitis C
Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for an investigational, pan-genotypic, once-daily tablet containing the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection.
The CHMP positive opinion was adopted following an accelerated review procedure, reserved for medicinal products expected to be of major public health interest. The recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union, Norway and Iceland.
You may be interested
Anafi: Straight out of the Greek MythologyPanos - Aug 17, 2017
Greek Mythology has it that Anáfi, a paradise of pristine beauty and “exotic” beaches washed by crystal clear waters, had…
Greek Government to Invest in Kastellorizo Island DesalinationPanos - Aug 17, 2017
Greece’s General Secretariat for the Aegean and Island Policy and the country’s shipping industry have signed a €870,000 ($1 million)…